InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-02 | 2026-04-03 | Higgins Jack | Chief Scientific Officer | Sale | 9,438 | $21.64 | $204K | 22.0K | View ↗ | |
| 2026-04-02 | 2026-04-03 | Rosett Max | Chief Financial Officer | Sale | 65.0K | $21.92 | $1.42M | 54.0K | View ↗ | |
| 2026-03-27 | 2026-03-31 | SIEGALL CLAY B | Director & President and CEO | Purchase | 25.4K | $19.67 | $501K | 690.7K | View ↗ | |
| 2026-03-23 | 2026-03-23 | WAGENHEIM PHILIP | Director | Sale | 28.2K | $20.65 | $582K | 341.1K | View ↗ | |
| 2026-03-20 | 2026-03-23 | WAGENHEIM PHILIP | Director | Sale | 36.8K | $20.47 | $753K | 369.3K | View ↗ |
No annual data found.
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid Tumors
Assessing Immunome (IMNM) Valuation After Varegacestat NDA And Phase 3 Desmoid Tumor Success
Techne (TECH) Misses Q3 Earnings and Revenue Estimates